Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

HYALURONIDASE-OCSQ\OCRELIZUMAB for Primary progressive multiple sclerosis: Side Effects & Safety Data

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

There are 14 adverse event reports in the FDA FAERS database where HYALURONIDASE-OCSQ\OCRELIZUMAB was used for Primary progressive multiple sclerosis.

Most Reported Side Effects for HYALURONIDASE-OCSQ\OCRELIZUMAB

Side Effect Reports % Deaths Hosp.
Injection site erythema 23 13.5% 0 2
Off label use 21 12.3% 0 1
Injection site pain 20 11.7% 0 2
Contusion 17 9.9% 0 1
Fatigue 17 9.9% 0 0
No adverse event 13 7.6% 0 0
Pain 13 7.6% 0 0
Erythema 12 7.0% 0 0
Injection site reaction 12 7.0% 0 0
Headache 10 5.9% 0 0
Injection site swelling 10 5.9% 0 2
Rash 10 5.9% 0 0
Swelling 8 4.7% 0 0
Pain in extremity 7 4.1% 0 0
Multiple sclerosis relapse 6 3.5% 0 1

Other Indications for HYALURONIDASE-OCSQ\OCRELIZUMAB

Multiple sclerosis (65) Product used for unknown indication (41) Relapsing multiple sclerosis (32) Relapsing-remitting multiple sclerosis (20)

Other Drugs Used for Primary progressive multiple sclerosis

OCRELIZUMAB (6,156) RITUXIMAB (147) DALFAMPRIDINE (71) FINGOLIMOD (66) SIPONIMOD (60) UNSPECIFIED INGREDIENT (34) OFATUMUMAB (32) GLATIRAMER (30) INTERFERON BETA-1A (27) NATALIZUMAB (27)

Related Pages

HYALURONIDASE-OCSQ\OCRELIZUMAB Full Profile All Primary progressive multiple sclerosis Drugs HYALURONIDASE-OCSQ\OCRELIZUMAB Demographics HYALURONIDASE-OCSQ\OCRELIZUMAB Timeline